DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 3 Jim Cramer - 2 Lilly - 2 Jim Cramer's - 2 Jim - 2 Goldman Sachs - 1 Piper Sandler - 1 — - 1
Top related locs:
Danish GLP North Carolina Novo Denmark Zepbound Alzheimer's U.S
Top related orgs:
Novo Nordisk's semaglutide - 3 CNBC - 2 Nasdaq - 1 Apple - 1 Big Tech - 1 Nvidia - 1 Club - 1 Blackwell - 1

Search resuls for: "Novo Nordisk's semaglutide"


3 mentions found


☆ Here's why KeyBanc analysts see more than 40% upside for Nvidia stock
  + stars: | 2024-07-09 | by ( Morgan Chittum | ) www.cnbc.com   time to read: +2 min
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. KeyBanc raised its price target on the Club chipmaker's stock to $180 per share from $130. New research indicated that tirzepatide, the active ingredient in Lilly's Mounjaro for diabetes and Zepbound for weight loss leads to more weight loss than Novo Nordisk's semaglutide. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.
Persons: Jim Cramer, Goldman Sachs, Piper Sandler, —, KeyBanc, Eli Lilly, Lilly, Jim Cramer's, Jim Organizations: CNBC, Nasdaq, Apple, Big Tech, Nvidia, Club, Blackwell, Novo Nordisk's semaglutide
☆ AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead
  + stars: | 2023-11-10 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +8 min
Eli Lilly (LLY) remains our favorite way to play the weight-loss drug market, despite a new entry this week from AstraZeneca (AZN). Eli Lilly shares had their worst day of the year Thursday, falling 4.5% in the session to close at $591.32. AstraZeneca's encroachment on turf currently dominated by Eli Lilly and Danish rival Novo Nordisk (NVO) may have contributed to Thursday's declines. That approval, despite being widely expected, pushed Eli Lilly to an all-time closing high Wednesday, at $619.13 per share. Our desire to own Eli Lilly over Novo Nordisk hinges, in part, on our confidence in Eli Lilly's other treatment opportunities, such as in Alzheimer's.
Persons: Eli Lilly, Jim Cramer, Jim, Lilly's, Eli Lilly's tirzepatide, Zepbound, Novo's, Eli Lilly's, Eli Lilly's GLP, Dave Ricks, Lilly, Ricks, AstraZeneca's, ECC5004, retatrutide, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: AstraZeneca, Novo Nordisk, American Heart Association, Novo Nordisk's semaglutide, CNBC, Reuters, Citigroup Locations: Danish, GLP, North Carolina, Novo, Denmark, Zepbound, Alzheimer's
☆ Bank of America sees risks for employers as insurance coverage of weight loss drugs grows
  + stars: | 2023-10-11 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +4 min
The eye-popping predictions for weight loss drug sales hinge on insurance companies agreeing to provide coverage of the pricey treatments, and momentum seems to be building on that front. The drugs include Novo Nordisk's semaglutide, which is sold as Ozempic for diabetes management and as Wegovy for weight loss. Unlike earlier generations of weight loss medicines, their side effects have been largely mild and included diarrhea, constipation and nausea. Higher hospital labor costs as well as GLP-1 medications are contributing to the biggest jump in health insurance costs since 2012, Lutz said. But those numbers will grow, especially as ongoing research continues to make the case for benefits beyond blood sugar control and weight loss.
Persons: Allen Lutz, Lutz, Lutz's, Savanta, Accolade, Eli Lilly, Mercer, Willis Towers Watson, Peter Verdult, Verdult, — CNBC's Michael Bloom Organizations: Bank of America, Accolade, Novo Nordisk's semaglutide, Food, Drug Administration, Citi, Nordisk, Centers for Disease Control Locations: U.S
0 next >>
Total: 3